|
|
|
|
Harvard Symposium on Mesothelioma by the International Mesothelioma Program: List of Presentations, years 2005-2009 Director: David J. Sugarbaker, MD
Co Directors: Gavin Gordon, PhD (2006-2008)
Tamara Tilleman, MD, PhD (2009)
| | 2009 | | November 19, 2009 | "Targeting of Core Apoptosis Pathways in Malignant Pleural Mesothelioma for Effective Therapy"
Dean A. Fennell, PhD, FRCP, FRCPI,
Cancer Research UK Clinician Scientist,
Consultant and Reader in Thoracic Medical Oncology,
Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland | | July 24, 2009 | Worldwide Mesothelioma Trends
Julian Peto
London School of Hygiene and Tropical Medicine and Institute of Cancer | | June 5, 2009 | Mesothelin Targeted Immunotherapy in Combination with Chemotherapy for Malignant Mesothelioma
Raffit Hassan, MD
Chief of Solid Tumor Immunotherapy Section
Laboratory of Molecular Biology, National Cancer Institute | | | 2008 | | May 30, 2008 | Mechanistic Insights and Lessons Learned from Mouse Models of Malignant Mesothelioma
Deborah Altomare, MD
Fox Chase Cancer Center
Human and Mouse Mesotheliomas
A Mouse Model Recapitulating Molecular Features of Human Mesothelioma | | April 11, 2008 | Extrapleural Pneumonectomy vs. Pleurectomy Decortication
Raja M. Flores MD
Memorial Sloan-Kettering Cancer Center | | January 4, 2008 | Marker Discovery for Mesothelioma
Harvey I. Pass MD
New York University School of Medicine | | | 2007 | | December 7, 2007 | Photodynamic Therapy for Mesothelioma - Past, Present & Future
Joseph S. Friedberg MD
Penn Presbyterian Medical Center | | November 2, 2007 | Twenty-five years of fiber analysis: What have we learned?
Victor L. Roggli, MD
Duke | | October 5, 2007 | Chemotherapy: It's Role in Pleural Mesothelioma
Nicholas Vogelzang MD
Nevada Cancer Institute | | September 7, 2007 | Interaction of mineral and fibers with genetic & viruses in the pathogeneis of Mesothelioma
Michele Carbone, MD, Ph.D.
University of Hawaii | | | 2006 | | December 12, 2006 | IGF Axis Activation in Mesothelioma
Robert Kratzke, M.D. | | November 17, 2006 | Testing Anti-Apoptotic Strategies Using 3DModels ofMesothelioma
V. Courtney Broaddus, M.D.
Dr. Broaddus' Research | | October 13, 2006 | Serum and Pleural Effusion Biomarkers for Mesothelioma".
Jenette Creaney, Ph.D. | | September 22, 2006 | Molecular Prognosis of Mesothelioma: An Update
Raphael Bueno, M.D. | | June 9, 2006 | Radiation Sensitization via Inhibiting Survival of Mesothelioma and its Vascular Endothelium
Bo Lu, MD, PhD | | May 12, 2006 | Household Exposure to Asbestos - What's the Data
Michael P. Thornton, Esq. | | May 5, 2006 | Systemic Therapy for Mesothelioma and Novel Agents
Hedy Lee Kindler, MD
Systemic Treatments for Mesothelioma: Standard and Novel | | April 21, 2006 | In Vitro Studies of Human Mesothelial Cells with Asbestos
John F. Lechner, PhD
In Vitro Studies of Human Mesothelial Cells with Asbestos | | April 7, 2006 | Ramifications of Proposed Federal and State Asbestos Legislation as it relates to patient care
Paul J. Doolittle, Esq | | March 31, 2006 | SV40 and Mesothelioma
Adi F. Gazdar, MD
Article : Molecular Pathogenesis of Malignant Mesothelioma & its Relationship to Simian Virus 40. | | March 17, 2006 | Murine Models of Asbestos-Induced Malignant Mesothelioma
Agnes B. Kane, MD, PhD | | March 3, 2006 | Immunophenotype of Sarcomatoid Malignant Mesothelioma
Lucian R. Chirieac, MD | | February 17, 2006 | Surgery and PDT in the Multimodality Treatment of Malignant Pleural Mesothelioma
Stephen Hahn, MD | | February 3, 2006 | A Brief History of the Development of Medical and Corporate Knowledge Concerning Asbestos Disease
Russell W. Budd, Esq.
Early Scientific and Medical Literature | | January 20, 2006 | World of Mesothelioma Epidemiology
Gary M. Strauss, MD, MPH | | | 2005 | | December 9, 2005 | Cell Signaling Pathways in Survival and Chemoresistance in Mesothelioma
Brooke T. Mossman, PhD
PPT Presentation | | December 2, 2005 | Measuring Quality of Life of Patients with Pleural Mesothelioma
Patricia Hollen, PhD
PPT Presentation
Quality of Life | | November 11, 2005 | Overcoming Chemotherapeutic Resistance in Mesothelioma: Targeting the Inhibitor of Apoptosis Family of Proteins
Gavin J. Gordon, PhD
Inhibitor of Apoptosis Protein-1 | | November 4, 2005 | NF2: Biology and Therapeutic Relevance
Joseph R. Testa, PhD
Evidence For a Two-Hit Mechanism of NF2 Inactivation | | October 28, 2005 | Industrial and Non-Occupational Exposure to Asbestos
Cora Roelofs, ScD
Current Issues in Asbestos Exposure | | October 21, 2005 | MRT and Mesothelioma - Where are We?
Aaron M. Allen
IMRT planning for mesothelioma | | October 14, 2005 | Gene Expression Profiling Studies of Mesothelioma: Biology, Prognostication and Therapeutic Leads
Marc Ladanyi, MD
The Ladanyi Lab
Analogues of the Nonpolyglutamatable Dihydrofolate | | October 7, 2005 | Mining Talc Data – Observations on Talc and Related Particles in Tissues: From Trivial Talc Exposure to Fatal Malignant Mesothelioma
Jerrold L. Abraham, MD
Article : Particle Size for Differentiation between Inhalation and Injection Pulmonary Talcosis. | | September 23, 2005 | Talopterin (PT523): A New Potent Nonpolyglutamatable Antifolate in Phase I Trial
Andre Rosowsky, PhD | | September 16, 2005 | Pathogenesis of Mesothelioma – Asbestos to Cancer
John J. Godleski, MD
Role of asbestos in etiology of malignant pleural mesothelioma |
|
 Send Feedback to: Tamara Tillman at ttilleman@partners.org
This page was last modified on 11/19/2009
|
|
|
 |
